List of Excipients in Branded Drug LISDEXAMFETAMINE DIMESYLATE

Generic Drugs Containing LISDEXAMFETAMINE DIMESYLATE

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	lisdexamfetamine dimesylate	0054-0370	AMMONIA
Hikma Pharmaceuticals USA Inc	lisdexamfetamine dimesylate	0054-0370	BUTYL ALCOHOL
Hikma Pharmaceuticals USA Inc	lisdexamfetamine dimesylate	0054-0370	CALCIUM PHOSPHATE
Hikma Pharmaceuticals USA Inc	lisdexamfetamine dimesylate	0054-0370	CELLULOSE, MICROCRYSTALLINE
Hikma Pharmaceuticals USA Inc	lisdexamfetamine dimesylate	0054-0370	FERRIC OXIDE YELLOW
Hikma Pharmaceuticals USA Inc	lisdexamfetamine dimesylate	0054-0370	FERROSOFERRIC OXIDE

What are the Most Frequently-Used Excipients in LISDEXAMFETAMINE DIMESYLATE?

# Of NDCs	Excipient
4	ALCOHOL
9	AMMONIA
2	ANHYDROUS CITRIC ACID
5	BUTYL ALCOHOL
2	CALCIUM PHOSPHATE
23	CELLULOSE, MICROCRYSTALLINE

Lisdexamfetamine Dimesylate Excipient Strategy and Commercial Opportunities

Last updated: August 14, 2026

Lisdexamfetamine dimesylate has a relatively simple immediate-release formulation, with capsule and chewable-tablet products relying on conventional excipients rather than a complex delivery system. The main commercial opportunities are in pediatric acceptability, sugar reduction, color-free products, differentiated chewables, supply-chain security, and generic cost optimization. Core composition and use patents for Vyvanse have expired, shifting value from exclusivity to manufacturing execution, regulatory compliance, product design, and reliable excipient sourcing.

What is the formulation profile of lisdexamfetamine dimesylate?

Lisdexamfetamine is a covalent prodrug of dextroamphetamine linked to L-lysine. It is converted primarily in red blood cells after absorption. The excipient system does not create the principal pharmacokinetic effect or determine the prodrug mechanism. It supports tablet manufacture, disintegration, stability, taste, appearance, and patient acceptability.

The principal U.S. reference product is Vyvanse, marketed by Takeda Pharmaceuticals. FDA-approved dosage forms include:

Dosage form	Typical strengths	Primary commercial use
Hard gelatin capsule	10, 20, 30, 40, 50, 60, 70 mg	ADHD and binge-eating disorder
Chewable tablet	10, 20, 30, 40, 50, 60 mg	Patients who have difficulty swallowing capsules
Active ingredient	Lisdexamfetamine dimesylate	Schedule II central nervous system stimulant

The label identifies conventional excipients in the capsule, including microcrystalline cellulose, croscarmellose sodium, magnesium stearate, gelatin, titanium dioxide, and colorants. The chewable tablet uses microcrystalline cellulose, croscarmellose sodium, magnesium stearate, colloidal silicon dioxide, fructose, and sucralose, among other product-specific components (FDA, 2023a; FDA, 2023b).

What excipients are used in Vyvanse capsules and chewable tablets?

Capsule excipients

The capsule formulation uses a standard direct-compression or dry-granulation excipient platform:

Excipient	Likely function	Strategic relevance
Microcrystalline cellulose	Diluent and compressibility aid	Supports robust fill weight and content uniformity
Croscarmellose sodium	Superdisintegrant	Promotes rapid capsule-content dispersion
Magnesium stearate	Lubricant	Controls ejection and tooling friction
Gelatin	Capsule shell	Creates swallowing and appearance differentiation
Titanium dioxide	Opacifier and color modifier	Supports dose-strength identification
Iron oxides or certified colorants	Capsule color	Reduces medication-selection errors but adds regulatory complexity
Printing ink	Product identification	Supports branding and strength differentiation

A capsule product has a low formulation barrier. Generic manufacturers can usually replicate the excipient functions with widely available materials, subject to inactive-ingredient limits, quality controls, and bioequivalence requirements.

Chewable-tablet excipients

The chewable tablet has greater commercial differentiation potential because it must satisfy mechanical, sensory, and dose-uniformity requirements simultaneously.

Excipient	Likely function	Strategic relevance
Microcrystalline cellulose	Diluent and structure former	Supports tablet integrity
Croscarmellose sodium	Disintegrant	Accelerates breakup during chewing or swallowing
Fructose	Sweetener and bulking agent	Improves palatability but limits use in some patients
Sucralose	High-intensity sweetener	Improves sweetness at low concentration
Colloidal silicon dioxide	Glidant and moisture-control aid	Improves powder flow and manufacturing consistency
Magnesium stearate	Lubricant	Supports tableting performance
Flavor system	Taste masking	Major determinant of repeat use and pediatric acceptance

The chewable form is more sensitive to particle size, flavor release, aftertaste, tablet hardness, friability, and compression force. Taste-masking performance may create a stronger practical barrier than the underlying patent estate.

What excipient strategy is best for generic lisdexamfetamine?

A generic manufacturer should use a risk-adjusted strategy rather than pursue unnecessary formulation novelty.

Strategy 1: Match the reference product closely

The lowest regulatory risk is a functionally similar capsule using standard grades of microcrystalline cellulose, croscarmellose sodium, and magnesium stearate. The target is rapid disintegration, comparable dissolution, acceptable content uniformity, and stable assay through shelf life.

This strategy is appropriate when the objective is rapid ANDA approval and low cost. It provides limited differentiation and exposes the product to price competition once multiple generic suppliers enter.

Strategy 2: Optimize excipient grades for manufacturing cost

The active dose of lisdexamfetamine is small relative to total capsule or tablet mass. Excipient performance therefore has an outsized effect on blend uniformity and dose-control risk.

Useful optimization variables include:

• Microcrystalline cellulose particle-size distribution.
• Croscarmellose sodium substitution level.
• Lubrication time and magnesium stearate concentration.
• Powder flow and segregation behavior.
• Capsule-fill weight and machine-speed tolerance.
• Moisture content and packaging configuration.
• API particle-size distribution and bulk density.

A lower-cost excipient can reduce unit economics only if it does not increase blend segregation, dissolution variability, rejection rates, or stability failures. For a Schedule II product, production interruption has greater commercial impact because quota planning and controlled-substance inventory controls limit rapid recovery.

Strategy 3: Develop a differentiated chewable

The chewable tablet offers the strongest formulation opportunity. Potential improvements include:

• Sugar-reduced or sugar-free formulations.
• Improved flavor systems with lower aftertaste.
• Smaller tablets for children.
• Reduced friability and better chew texture.
• Color-free or lower-color products.
• Improved moisture resistance.
• Alternative sweetener systems for patients who avoid fructose.
• Packaging that supports adherence and controlled-substance accountability.

A sugar-free formulation could target patients with fructose intolerance, diabetes-related dietary restrictions, or parental preference for reduced sugar. It would require sensory testing and likely a new excipient compatibility program. Replacing fructose with mannitol, xylitol, isomalt, or another polyol may introduce cooling effects, laxation risk, hygroscopicity, or altered compression behavior.

What formulation patents protect lisdexamfetamine?

The principal pharmaceutical composition and prodrug patents associated with Vyvanse have expired or reached the end of their U.S. exclusivity period. The important commercial change occurred in 2023, when FDA approvals of generic lisdexamfetamine products began following expiration of the principal Vyvanse protection.

Protection category	Commercial status
Lisdexamfetamine chemical composition	Core protection expired in the United States
Immediate-release capsule formulation	No longer a meaningful standalone barrier where covered patents have expired
Chewable tablet	Generic entry enabled after applicable listed patent and exclusivity periods ended
ADHD method of use	Expired or no longer sufficient to block broad generic entry
Binge-eating disorder method of use	Expired or no longer sufficient to preserve product-wide exclusivity
Manufacturing processes	May remain relevant by jurisdiction and claim scope, but process protection does not automatically block all alternative synthesis routes
Trade secrets and know-how	Can remain commercially relevant after patent expiration

The FDA Orange Book and Drugs@FDA records are the controlling sources for listed patents, pediatric exclusivity, and regulatory status. U.S. Patent No. 7,105,486 is among the patents historically associated with lisdexamfetamine protection. The relevant protection period ended in 2023, enabling generic competition (FDA, 2023c; U.S. Patent and Trademark Office, 2023).

When did lisdexamfetamine lose exclusivity?

Vyvanse lost effective U.S. market exclusivity in 2023. FDA approved multiple generic lisdexamfetamine products beginning in August 2023, including capsule products and, in some cases, chewable tablets.

Exclusivity timeline

Event	Timing
Vyvanse U.S. approval	2007
ADHD indication expanded over product life cycle	2008 onward
Binge-eating disorder approval	2015
Core U.S. patent protection reached expiration	2023
Pediatric exclusivity period	Extended the effective protection period into 2023
First major generic approvals	August 2023
Broad generic availability	Late 2023 onward, subject to supply and launch decisions

Lisdexamfetamine is not a biologic. Biosimilar rules do not apply. The relevant competitive pathway is the ANDA process for generic drugs, not the abbreviated biologics pathway.

Which companies challenged Vyvanse patents?

Multiple generic manufacturers pursued ANDA approval for lisdexamfetamine capsules and chewable tablets. Publicly reported participants included Teva Pharmaceuticals, Sandoz, Sun Pharmaceutical Industries, Apotex, Zydus, and other generic companies.

The challenges generally relied on Paragraph IV certifications asserting that listed patents were invalid, unenforceable, or would not be infringed. The expiration of the principal patent and pediatric-exclusivity period reduced the ability of patent litigation to delay generic entry beyond 2023.

Paragraph IV risk remains relevant for later-developed products only if a manufacturer obtains new patents covering a specific formulation, manufacturing process, or delivery system. Such patents would not automatically restore product-wide exclusivity for standard lisdexamfetamine capsules.

What is the FDA regulatory status of lisdexamfetamine?

Lisdexamfetamine dimesylate is FDA-approved for:

• Attention-deficit/hyperactivity disorder in patients aged six years and older.
• Moderate to severe binge-eating disorder in adults.

It is a Schedule II controlled substance in the United States. A generic sponsor must manage controlled-substance registration, quota allocation, security controls, inventory reconciliation, serialization where applicable, diversion risk, and DEA compliance in parallel with FDA requirements.

The excipient system is evaluated through the ANDA’s pharmaceutical equivalence, bioequivalence, quality, manufacturing, and labeling requirements. A new chewable or modified product may require more extensive development than a conventional capsule, especially if it changes release behavior, dosing convenience, or administration instructions.

How strong is the patent estate for lisdexamfetamine today?

The remaining patent estate is weak as a barrier to conventional generic capsules. The core molecule and principal branded dosage forms are commercially exposed to generic competition.

Patent strength is higher for narrowly defined innovations, including:

• New taste-masked chewable formulations.
• Sugar-free or allergen-reduced compositions.
• Improved moisture-stable tablets.
• Pediatric dosage flexibility.
• Novel multiparticulate or sprinkle systems.
• Manufacturing processes with measurable purity or yield advantages.
• Packaging or dispensing systems that improve controlled-substance security.
• Combination products or new therapeutic uses, where legally and clinically supportable.

The commercial value of a new patent depends on whether it can block a clinically substitutable product. A narrow chewable patent may protect a premium product while leaving capsule generics unaffected.

What commercial opportunities exist for excipient suppliers?

Excipient suppliers can capture value even without owning active-ingredient patents. The strongest opportunities are supply reliability, technical differentiation, and regulatory support.

High-value excipient opportunities

Opportunity	Commercial rationale
Direct-compression microcrystalline cellulose	Supports high-throughput manufacture and content uniformity
Low-moisture excipient grades	May improve stability and packaging flexibility
Co-processed excipients	Can improve flow, compaction, and disintegration
Taste-masking systems	Creates differentiation for pediatric chewables
Sugar-free bulking agents	Supports reformulation of chewable tablets
Natural or color-free systems	Addresses parent and patient preferences
Controlled particle-size materials	Reduces segregation and blend variability
Excipient supplier qualification packages	Shortens customer development and filing work
Dual-source supply programs	Reduces interruption risk for high-volume generics

Suppliers with Type IV Drug Master Files, strong change-control systems, compendial compliance, and global regulatory documentation are better positioned than commodity suppliers. For a low-margin generic, supply interruption can be more damaging than a modest unit-price difference.

What manufacturing and intellectual-property barriers remain?

The largest barriers are operational rather than composition-patent based.

Manufacturing barriers

Lisdexamfetamine products require control of:

• Low-dose API distribution within the blend.
• Powder segregation during transfer and capsule filling.
• Lubrication effects on dissolution and content uniformity.
• Moisture exposure.
• API and excipient compatibility.
• Controlled-substance security.
• Batch-size scale-up.
• Cleaning validation and cross-contamination controls.
• Packaging integrity over the proposed shelf life.

Chewable tablets add taste, texture, friability, and patient-acceptance requirements. A product can meet basic pharmaceutical specifications and still underperform commercially if children reject the taste or texture.

Intellectual-property barriers

Process patents may affect a specific synthetic route even after composition patents expire. A generic sponsor can reduce risk by using an alternative route, securing a license, or documenting a non-infringement position. Trade secrets around crystallization, impurity control, yield, and scale-up may provide competitive advantages without preventing market entry.

What licensing deals affect lisdexamfetamine?

The major commercial relationship is Takeda’s ownership and commercialization of Vyvanse following its acquisition of Shire. The lisdexamfetamine opportunity is now more relevant to generic manufacturers, contract development and manufacturing organizations, excipient suppliers, and specialty product developers than to a new originator seeking broad molecule-level exclusivity.

Potential licensing structures include:

• Regional rights for generic capsules.
• Chewable-tablet technology licenses.
• Taste-masking or sugar-free formulation licenses.
• API supply agreements.
• Process licenses for high-purity, high-yield synthesis.
• Co-development agreements with pediatric-product specialists.
• Authorized-generic arrangements.

A formulation license is most defensible when it includes enforceable patents, validated sensory data, regulatory-support documentation, and a clear premium or market-access rationale.

How does lisdexamfetamine compare with competing ADHD drugs?

Product	Active ingredient	Formulation opportunity	Exclusivity profile
Vyvanse/generic lisdexamfetamine	Lisdexamfetamine dimesylate	Chewable, capsule, pediatric acceptability	Core U.S. protection expired in 2023
Adderall XR/generics	Mixed amphetamine salts	Extended-release delivery and capsule systems	Mature generic market
Concerta/generics	Methylphenidate hydrochloride	Osmotic or extended-release delivery	Complex delivery patents historically important
Quillivant XR	Methylphenidate	Oral suspension and taste masking	Liquid formulation differentiation
Jornay PM	Methylphenidate	Delayed-release evening dosing	Timing-of-delivery differentiation
Dyanavel XR	Amphetamine	Liquid and extended-release formats	Pediatric dosage-form differentiation
Azstarys	Serdexmethylphenidate/dexmethylphenidate	Prodrug and extended-release combination	Newer product and formulation protection

Lisdexamfetamine’s advantage is a comparatively simple immediate-release dosage-form platform combined with prodrug pharmacology. Its weakness for future commercial growth is the loss of core exclusivity and the availability of multiple generic substitutes.

What generic launch scenarios exist?

Low-price capsule launch

This is the most likely high-volume strategy. Manufacturers compete on cost, wholesaler access, supply reliability, and payer contracts. Excipient differentiation has little effect on prescribing unless it produces a meaningful tolerability or supply advantage.

Premium chewable launch

A manufacturer can seek a premium position through improved taste, lower sugar, color-free design, or smaller tablets. The product must demonstrate practical value because pharmacies and payers may substitute lower-cost alternatives.

Pediatric adherence platform

A chewable product combined with flexible strengths, adherence packaging, and patient-support services could target children who cannot swallow capsules. The opportunity depends on payer coverage and physician willingness to prescribe a differentiated generic.

Supply-constrained market entry

Controlled-substance shortages can create temporary openings for manufacturers with reliable API, excipient, and packaging supply. These openings are commercially valuable only if the manufacturer can sustain allocation and meet DEA and FDA requirements.

What is the revenue exposure from Vyvanse loss of exclusivity?

Vyvanse generated approximately $2.5 billion in annual sales before generic erosion, making it one of Takeda’s significant mature-product exposures. After generic entry, branded revenue faces price compression, formulary substitution, and channel inventory effects. The decline rate depends on generic availability, pharmacy substitution, supply shortages, authorized-generic arrangements, and branded patient retention (Takeda Pharmaceutical Company Limited, 2023).

For generic entrants, the total market opportunity is large but structurally competitive. The principal value drivers are manufacturing scale, API access, launch timing, wholesaler contracts, and the ability to maintain supply. Excipient cost savings alone are unlikely to determine market share.

Key Takeaways

• Lisdexamfetamine dimesylate uses conventional excipients in both capsules and chewable tablets.
• The capsule platform has limited formulation complexity and is relatively accessible to generic manufacturers.
• The chewable tablet offers greater room for differentiation through taste, texture, sugar reduction, and pediatric design.
• Core U.S. Vyvanse patent protection and effective exclusivity ended in 2023.
• Paragraph IV litigation no longer creates a broad barrier to standard generic entry.
• Lisdexamfetamine is a small-molecule controlled substance, not a biologic, so biosimilar risk is inapplicable.
• Excipient suppliers can compete through low-moisture grades, co-processed materials, taste masking, dual sourcing, and regulatory documentation.
• The principal remaining barriers are controlled-substance compliance, low-dose blend uniformity, process know-how, supply reliability, and commercial scale.
• Revenue exposure from Vyvanse loss of exclusivity was material because pre-generic annual sales were approximately $2.5 billion.
• Premium commercial opportunities are concentrated in chewables, pediatric products, sugar-free systems, and supply-secure generic platforms.

FAQs

Can lisdexamfetamine be formulated as an orally disintegrating tablet?

Yes, an orally disintegrating or rapidly dispersible product could be developed, but it would require control of taste, tablet strength, moisture sensitivity, dose uniformity, and disintegration performance. It may also require new patent claims to support premium positioning.

Is fructose in the Vyvanse chewable tablet a commercial vulnerability?

Yes. Fructose can limit use by patients with fructose intolerance or dietary restrictions. Replacing it with a polyol or another bulking agent creates an opportunity, but the reformulation must address cooling sensation, gastrointestinal tolerability, hygroscopicity, and tablet robustness.

Do excipients affect lisdexamfetamine abuse-deterrent properties?

The principal prodrug-related pharmacology arises from enzymatic conversion of lisdexamfetamine to dextroamphetamine, not from a specialized excipient matrix. Excipients can affect release, crushing behavior, and administration characteristics, but they do not independently reproduce the prodrug mechanism.

Can an excipient supplier patent a lisdexamfetamine formulation?

Yes. A supplier or drug developer may patent a formulation containing specific excipient ranges, taste-masking systems, particle attributes, stability improvements, or manufacturing steps. Patent value depends on claim breadth and whether a substitutable generic can avoid the claims.

Is a new lisdexamfetamine chewable likely to receive three years of FDA exclusivity?

A qualifying new clinical investigation supporting approval of a new dosage form or indication may support three-year exclusivity under the Hatch-Waxman framework. A routine generic formulation change without qualifying clinical data generally does not receive that protection.

References

1. Food and Drug Administration. (2023a). Vyvanse (lisdexamfetamine dimesylate) capsules prescribing information. U.S. Department of Health and Human Services.

2. Food and Drug Administration. (2023b). Vyvanse (lisdexamfetamine dimesylate) chewable tablets prescribing information. U.S. Department of Health and Human Services.

3. Food and Drug Administration. (2023c). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.

4. Food and Drug Administration. (2023d). Drugs@FDA: Vyvanse application and approval history. U.S. Department of Health and Human Services.

5. Takeda Pharmaceutical Company Limited. (2023). Annual report 2023. Tokyo, Japan.

6. U.S. Patent and Trademark Office. (2023). Patent Center and patent term information for U.S. Patent No. 7,105,486. U.S. Department of Commerce.